News

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...
On the diesel front, the 300 SD straight-six lump with 148 horsepower and 229 pound-feet (310 Nm) of torque had to suffice. As for the gasoline-loving customers, they were offered a sixer in the ...
Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.
The heftiest member of the W140 S-class line — the S600 SEL — featured a fearsome 5,987cc V12 engine with an output of 408 horsepower. Open it up on the highway, and you're looking at top ...
Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...
PHOENIX – A long-time leader in iron innovation and performance, today PING introduced the Blueprint S and Blueprint T, two new forged iron models engineered and custom-built for golfers seeking ...
The Blueprint became law in 2021 after the General Assembly overrode a veto of the bill by former Gov. Larry Hogan. The Kirwan Commission was formed in 2016 and worked for three years to develop ...
Sacco has always been a household name at the Three-Point Star and is credited as being the father of the W126, W140, and W220 generations of S-Class, to the R129 SL Roadster, the W202 and W203 C ...
The virtual artist, better known as vladimirloktionov on social media, has presented a W140 third-generation Mercedes-Benz S-Class as his latest unofficial, hypothetical, and independent design ...
Blueprint was prepared to spend $5,537,927 on the redesign. It is unclear where these funds will be shifted to now. The agency is still eager to work something out with FDOT if possible, but the ...
The two companies said on Monday that Sanofi would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade.
PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck ...